Shopping Cart

There are no products in your cart.

Dr Doug Fairlie

GROUP LEADER, CELL DEATH & SURVIVAL GROUP

More about Dr Doug Fairlie

I am especially excited about making discoveries in fundamental molecular and cellular processes and translating these findings into the development of new treatment strategies that will ultimately benefit cancer patients.

Doug Fairlie obtained his PhD in Biochemistry from Monash University in 1994. After a postdoctoral stint in the US at the State University New York, Buffalo, he returned to Australia in 1996 to work at the Centre for Immunology, St Vincent’s Hospital, Sydney where he was the lead protein chemist on projects involving TGF-b-related cytokines and a novel intracellular ion channel.

In 2001, Doug joined the Cancer and Haematology Division at the Walter and Eliza Hall Institute to continue work on cytokines including IL-6 family members. In 2003, he moved to the Structural Biology Division at WEHI where he commenced working on cell death and survival mechanisms and was promoted to a laboratory head in 2010.

After joining ONJCRI in 2015, Doug is focused on understanding how cell death is regulated in melanoma and is working with colleagues at WEHI to develop new drugs targeting the apoptosis pathways in these and other tumours. His work is funded by grants from the NHMRC, Cancer Council of Victoria and Worldwide Cancer Research, UK.